Major depressive disorder (MDD) is a chronic relapsing psychiatric disorder. Conventional
antidepressants usually require several weeks of continuous administration to exert …

There is accumulating evidence demonstrating that dysfunction of glutamatergic
neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in …

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder.
Traditional antidepressants are of limited efficacy and take weeks to months to yield full …

Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR)
antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the …

Available treatments for depression have significant limitations, including low response rates
and substantial lag times for response. Reports of rapid antidepressant effects of a number …

The molecular mechanisms underlying major depressive disorder remain poorly
understood, and current antidepressant treatments have many shortcomings. The recent …

What is known and objective Abundant clinical data now confirm that ketamine produces a
remarkable rapid‐onset antidepressant effect–hours or days–in contrast to the delayed …

Current therapeutic options for major depressive disorder (MDD) and bipolar disorder (BD)
are associated with a lag of onset that can prolong distress and impairment for patients, and …

BACKGROUND: Ketamine exerts a robust, rapid, and relatively sustained antidepressant
effect in patients with major depression. Understanding the mechanisms underlying the …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …